Favorable safety and efficacy profile observed at 6 months and 1 year persisted at 2-year follow-up, demonstrating that the use of the Taxus stent prevents, rather than delays, in-stent restenosis.

In the SPIRIT IV trial of 3,690 patients, XIENCE V demonstrated the following key results at two years: A 30 percent risk reduction in TLF compared to TAXUS (6.9 percent for XIENCE V vs. 9.9 ...

EuroPCR 2006: "The TAXUS VI trial shows us that the TAXUS MR stent is extremely effective in treating high-risk patients with very complex lesions, and the results are sustained over the long term." ...

The FDA said it is investigating problems with Boston Scientific's Taxus stent after a Michigan hospital suspended use of the devices. William Beaumont Hospital in Royal Oak stopped using the ...